Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

Summary

The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.

Timeline

Start

2007-11

Primary completion

2008-10

Completion

2008-10

Outcome

Met primary endpoint

registry analysis (superiority or other test); Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD vs Pioglitazone 15 mg or 30 mg QD; Median Difference (Final Values) -0.717 (95% CI -0.848 to -0.586) NCT01318070 ↗

registry analysis (superiority or other test); Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD vs Pioglitazone 15 mg or 30 mg QD; Mean Difference (Final Values) -0.773 (95% CI -0.913 to -0.634) NCT01318070 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alogliptin	Unknown	12.5 mg	Oral
Subject	Alogliptin	Unknown	25 mg	Oral
Comparator	Pioglitazone	Small molecule	15 mg	Oral
Comparator	Pioglitazone	Small molecule	30 mg	Oral

Indications